LGM
Logos Global Management Portfolio holdings
AUM
$1.5B
1-Year Est. Return
197.64%
This Fund
S&P 500
1 Year Est. Return
+197.64%
AUM
$1.01B
AUM Growth
+$264M
(+35%)
Holding
71
Top Buys
| 1 | +$25.4M | |
| 2 | +$22.7M | |
| 3 | +$20.7M | |
| 4 |
LBRX
LB Pharmaceuticals
LBRX
|
+$17.9M |
| 5 |
Arvinas
ARVN
|
+$17.3M |
Top Sells
| 1 | +$30M | |
| 2 | +$26.5M | |
| 3 | +$24.4M | |
| 4 |
Neurocrine Biosciences
NBIX
|
+$18.9M |
| 5 |
Keros Therapeutics
KROS
|
+$17M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$19.7B
| $81.7M | 8.07% |
1,750,000
+50,000
|
|
||
2
IDEAYA Biosciences
IDYA
$2.83B
| $61.2M | 6.05% |
2,250,000
-1,095,000
|
|
||
|
AKRO
3
DELISTED
Akero Therapeutics
AKRO
| $57M | 5.63% |
1,200,000
|
|
||
|
4
Arvinas
ARVN
$852M
| $47.5M | 4.69% |
5,575,000
+2,275,000
|
|
||
5
Ocular Therapeutix
OCUL
$1.95B
| $38M | 3.75% |
3,250,000
+1,050,000
|
|
||
|
CDTX
6
DELISTED
Cidara Therapeutics
CDTX
| $35.9M | 3.55% |
375,000
+185,000
|
|
||
7
Verastem
VSTM
$431M
| $35.8M | 3.53% |
4,050,000
+3,050,000
|
|
||
|
ABVX
8
Abivax
ABVX
$9.59B
| $35.2M | 3.48% |
+415,000
|
|
||
9
Erasca
ERAS
$4.23B
| $33M | 3.26% |
15,150,000
+150,000
|
|
||
|
MAZE
10
Maze Therapeutics
MAZE
$2.19B
| $31.8M | 3.14% |
1,227,300
+615,386
|
|
||
11
Olema Pharmaceuticals
OLMA
$1.94B
| $31.4M | 3.1% |
3,208,875
|
|
||
12
Immunocore
IMCR
$1.64B
| $30.9M | 3.05% |
850,000
+275,000
|
|
||
13
Dyne Therapeutics
DYN
$2.57B
| $30.4M | 3% |
2,400,000
+500,000
|
|
||
14
Disc Medicine
IRON
$2.51B
| $29.7M | 2.94% |
450,000
-250,000
|
|
||
15
Design Therapeutics
DSGN
$595M
| $27.5M | 2.72% |
3,655,000
-562,627
|
|
||
16
Jazz Pharmaceuticals
JAZZ
$11.7B
| $26.4M | 2.6% |
200,000
-250,000
|
|
||
|
RNAM
17
Avidity Biosciences
RNAM
$11.2B
| $26.1M | 2.58% |
600,000
-350,000
|
|
||
18
Structure Therapeutics
GPCR
$4.45B
| $23.8M | 2.35% |
850,000
|
|
||
19
Janux Therapeutics
JANX
$819M
| $22.9M | 2.26% |
935,000
-65,000
|
|
||
20
Vaxcyte
PCVX
$8.86B
| $22.5M | 2.22% |
+625,000
|
|
||
21
Rhythm Pharmaceuticals
RYTM
$6.19B
| $20.2M | 2% |
200,000
+70,000
|
|
||
22
Trevi Therapeutics
TRVI
$1.53B
| $20.1M | 1.99% |
2,200,000
+1,350,000
|
|
||
23
Protagonist Therapeutics
PTGX
$5.76B
| $19.9M | 1.97% |
+300,000
|
|
||
24
Amylyx Pharmaceuticals
AMLX
$1.67B
| $19.7M | 1.95% |
+1,450,000
|
|
||
|
LBRX
25
LB Pharmaceuticals
LBRX
$607M
| $17.8M | 1.76% |
+1,130,000
|
|